explore -WSS

explore

author：entertainment 2025-08-12 05:31:37 - browse：36821

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

knowledge

WSS

What is microchimerism and how does it affect maternal health?

DeepMind touts AlphaFold's new skills as protein folding AI models face off

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Ed Silverman on new gene therapies, biosimilars, coffee, and more

explore

explore

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Continuity nursing helped my family in our darkest PICU moments

Medicare must police algorithms in Medicare Advantage, Dems say

Continuity nursing helped my family in our darkest PICU moments

Prime Medicine says its gene editing passes test in monkeys

Duchenne breakthrough therapy leaves behind pioneering families

Readout LOUD podcast: ESMO highlights & Roivant's big deal

Novavax promises a turnaround & Lilly roils the obesity market

The health care issue Democrats can’t solve: hospital reform

explore

6 phony surgeries that take placebo to the extreme

Lung cancer screening guidelines updated for cigarette smokers

Brain injuries and the importance of a second opinion

Inari Medical to buy amputation prevention company LimFlow

Antivenom research: Lessons from HIV applied in search for universal antidote

Alabama IVF ruling threatens families facing fatal genetic disease

explore

knowledge

focus

focus